1. Scrip
  2. >>New Products

Horizon Provides Assurances That Tepezza Sales Are Set To Soar

Guidance Maintained For 30% Growth In 2022

 
• By Mandy Jackson

Sales of the thyroid eye disease drug were impacted by surging COVID-19 case numbers in the first quarter, but the company is expanding its commercial team to capitalize on new TED market insights. 

Red-tailed Hawk flying over the mountains with sky background
Horizon expects more than 30% Tepezza sales growth in 2022 • Source: Shutterstock

COVID-19 continues to put pressure on Horizon Therapeutics plc’s Tepezza (teprotumumab), which quickly generated blockbuster-level sales despite its pandemic-era launch but experienced a sequential decline in sales during the first quarter. However, while the Omicron variant affected Q1 sales, the company is maintaining its guidance for mid-30% growth in 2022 and further investing in its commercial team to capitalize on recent thyroid eye disease (TED) market insights.

Horizon generated impressive results for Tepezza (teprotumumab) to date with $820m in 2020 sales after its launch in February of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Moderna’s Spikevax Wins Pediatric Approval, But With Narrower Label

 
• By Alaric DeArment

The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 
• By Andrew McConaghie

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By Manas Mishra

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.